Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$10.37 USD
+0.17 (1.67%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $10.40 +0.03 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Oric Pharmaceuticals, Inc. (ORIC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.38 | $25.00 | $14.00 | 80.20% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Oric Pharmaceuticals, Inc. comes to $18.38. The forecasts range from a low of $14.00 to a high of $25.00. The average price target represents an increase of 80.2% from the last closing price of $10.20.
Analyst Price Targets (8 )
Broker Rating
Oric Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
7/17/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/28/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
1/31/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $18.38 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.47 |